Characterization of the lung tumor microenvironment upon anti-PD-L1 therapy reveals an ambiguous role for TNF-α

被引：0

作者：

De Ridder, K. ^{[1
]}

Locy, H. ^{[1
]}

Piccioni, E. ^{[1
]}

Zuazo, M. Ibarra ^{[2
]}

Awad, R. M. ^{[1
]}

Verhulst, S. ^{[3
,4
]}

van Bulck, M. ^{[5
]}

De Vlaeminck, Y. ^{[1
]}

Lecocq, Q. ^{[1
]}

Reijmen, E. ^{[1
]}

De Mey, W. ^{[1
]}

De Beck, L.

Ertveldt, T. ^{[1
]}

Pintelon, I. ^{[6
]}

Timmermans, J-P. ^{[6
]}

Escors, D. ^{[2
]}

Keyaerts, M. ^{[7
]}

Breckpot, K. ^{[1
]}

Goyvaerts, C. ^{[1
]}

机构：

[1] Vrije Univ Brussel, Fac Med & Pharm, Dept Biomed Sci, Lab Mol & Cellular Therapy, Brussels, Belgium

[2] Navarrabiomed UPNA IdISNA, Immunomodulat Grp, Pamplona, Spain

[3] Dept Biomed Sci, Brussels, Belgium

[4] Liver Cell Biol Res Grp, Jette, Belgium

[5] Vrije Univ Brussel, Dept Biomed Sci, Lab Mol & Med Oncol, Jette, Belgium

[6] Univ Antwerp, Antwerp Ctr Adv Microscopy ACAM, Lab Cell Biol & Histol, Antwerp, Belgium

[7] Vrije Univ Brussel, Fac Med & Pharm, Invivo Cellular & Mol Imaging Lab, Jette, Belgium

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.02.200

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

168P

引用

页码：S109 / S109

页数：1

共 50 条

[21] Anti-PD-L1 therapy: patient selection is important
Peter Sidaway
Nature Reviews Clinical Oncology, 2016, 13 (3) : 134 - 134
[22] Discordance Among Biomarkers for Anti-PD1 Therapy Response: Tumor Mutational Burden and Anti-PD-L1 Staining
Hess, P. R.
Velu, P. D.
Bigdeli, A.
Morrissette, J. J.
Rosenbaum, J. N.
Roth, J.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (06): : 1039 - 1039
[23] Acidic tumor microenvironment-activated MRI nanoprobes for modulation and visualization of anti-PD-L1 immunotherapy
Fan, Kai
Yang, Xue
Tian, Fang-zheng
Li, Si-yu
Zhang, Jian-qiong
Xie, Jin-bing
Ju, Sheng-hong
NANO TODAY, 2024, 54
[24] Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
Swaika, Abhisek
Hammond, William A.
Joseph, Richard W.
MOLECULAR IMMUNOLOGY, 2015, 67 (02) : 4 - 17
[25] New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy
Chen, Cheng
Huang, Jian-An
EUROPEAN JOURNAL OF INFLAMMATION, 2016, 14 (01) : 61 - 65
[26] Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy
Tashireva, Liubov A.
Muravyova, Dariya T.
Popova, Natalya O.
Goldberg, Victor E.
Vtorushin, Sergey V.
Perelmuter, Vladimir M.
BIOCHEMISTRY-MOSCOW, 2021, 86 (11) : 1461 - 1468
[27] Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy
Liubov A. Tashireva
Dariya T. Muravyova
Natalya O. Popova
Victor E. Goldberg
Sergey V. Vtorushin
Vladimir M. Perelmuter
Biochemistry (Moscow), 2021, 86 : 1461 - 1468
[28] A rare case of pneumocystosis under anti-PD-L1 therapy
Santos, Maria Joao
Cavaco, Maria Joao
Santos, Fernanda Paula
Froes, Filipe
PULMONOLOGY, 2024, 30 (06): : 671 - 672
[29] Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment
Li, Huawei
You, Jia
Wei, Yuanfeng
Zheng, Lingnan
Yang, Ju
Xu, Jingyi
Li, Yue
Li, Zhaojun
Yang, Xi
Yi, Cheng
PHYTOMEDICINE, 2024, 123
[30] Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy
Li, Zhaoting
Wang, Yixin
Shen, Yuexin
Qian, Chenggen
Oupicky, David
Sun, Minjie
SCIENCE ADVANCES, 2020, 6 (20):

← 1 2 3 4 5 →